JW (Cayman) Therapeutics-B (02126) announced that on January 16, 2026, the company, pursuant to the terms of the post-IPO incentive plan adopted on October 14, 2020, granted a total of 2.6 million share options; concurrently, under the post-IPO restricted share unit plan also adopted on October 14, 2020, it granted a total of 650,000 restricted share units to four grantees of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.